New topics in the ACCP guideline include the perioperative management of patients receiving direct oral anticoagulants and P2Y12 inhibitor antiplatelet drugs.
Researchers sought to determine whether anticoagulation therapy using rivaroxaban would be effective in children with cancer-associated venous thromboembolism.
Researchers conducted an analysis of the Gab2-MALT1 pathway to determine whether it impacts the development of thromboinflammation and deep vein thrombosis.
Researchers explored the use of D-dimer levels to rule out PTE in patients with COVID-19, as well as clinical associations between D-dimer levels and PTE.
Researchers assessed the 30-day risk for VTE among ambulatory patients with COVID-19 and compared, via propensity-score matching, individuals without COVID-19 infection.
Researchers assessed the relationship between oral anticoagulation for patients with COVID-19 and AF and incidence of in-hospital thrombotic events and death.
Can the pulmonary embolism severity index assess the risk for adverse events among patients hospitalized for COVID-19 who are not diagnosed with PE or VTE?
The approval was based on data from the phase 3 ADVOCATE trial, which evaluated Tavneos in 330 adults with newly diagnosed or relapsed ANCA-associated vasculitis.
Researchers sought to determine whether prespecified outcomes were different in endovascular thrombectomy with alteplase compared with EVT alone in patients hospitalized with acute ischemic stroke.
Researchers sought to determine whether thromboprophylaxis with enoxaparin would reduce early hospitalizations and deaths among outpatients with symptomatic COVID-19.
Researchers sought to determine whether avatrombopag with MSCs would improve platelet recovery in patients with prolonged thrombocytopenia after allo-HSCT.
Researchers sought to assess whether patients with migraine had a greater risk for PCiS than ACiS and if patients genetically predisposed to migraine showed an increased risk for PCiS or ACiS.